Related Experiment Video
Updated: Dec 13, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
Phosphorylation of PLCγ1 by EphA2 Receptor Tyrosine Kinase Promotes Tumor Growth in Lung Cancer
Wenqiang Song1,2, Laura C Kim3, Wei Han4
1Division of Rheumatology and Immunology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Abstract:
EphA2 receptor tyrosine kinase (RTK) is often expressed at high levels in cancer and has been shown to regulate tumor growth and metastasis across multiple tumor types, including non-small cell lung cancer. A number of signaling pathways downstream of EphA2 RTK have been identified; however, mechanisms of EphA2 proximal downstream signals are less well characterized. In this study, we used a yeast-two-hybrid screen to identify phospholipase C gamma 1 (PLCγ1) as a novel EphA2 interactor. EphA2 interacts with PLCγ1 and the kinase activity of EphA2 was required for phosphorylation of PLCγ1. In human lung cancer cells, genetic or pharmacologic inhibition of EphA2 decreased phosphorylation of PLCγ1 and loss of PLCγ1 inhibited tumor cell growth in vitro. Knockout of PLCγ1 by CRISPR-mediated genome editing also impaired tumor growth in a KrasG12D-p53-Lkb1 murine lung tumor model. Collectively, these data show that the EphA2-PLCγ1 signaling axis promotes tumor growth of lung cancer and provides rationale for disruption of this signaling axis as a potential therapeutic option. IMPLICATIONS: The EphA2-PLCG1 signaling axis promotes tumor growth of non-small cell lung cancer and can potentially be targeted as a therapeutic option.
Insights
The EphA2-PLCγ1 signaling axis promotes non-small cell lung cancer growth. Targeting this pathway offers a potential therapeutic strategy for lung cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Signal Transduction
Background:
- EphA2 receptor tyrosine kinase (RTK) is upregulated in many cancers, including non-small cell lung cancer (NSCLC), and influences tumor progression.
- While downstream pathways of EphA2 are known, its immediate signaling mechanisms remain less understood.
Purpose of the Study:
- To identify novel proximal downstream interactors of EphA2.
- To investigate the role of the EphA2-PLCγ1 signaling axis in NSCLC tumor growth.
Main Methods:
- Yeast-two-hybrid screening to identify EphA2 interactors.
- In vitro studies using human lung cancer cells with genetic/pharmacologic inhibition of EphA2.
- CRISPR-mediated genome editing to knockout PLCγ1 in a murine lung tumor model.
Main Results:
- Phospholipase C gamma 1 (PLCγ1) was identified as a novel EphA2 interactor.
- EphA2 kinase activity is essential for PLCγ1 phosphorylation.
- Inhibition of EphA2 or PLCγ1 impaired NSCLC cell growth in vitro and in vivo.
- PLCγ1 knockout reduced tumor growth in a Kras-p53-Lkb1 murine lung cancer model.
Conclusions:
- The EphA2-PLCγ1 signaling axis is a key driver of lung cancer tumor growth.
- Disruption of the EphA2-PLCγ1 pathway represents a promising therapeutic strategy for NSCLC.
More Related Videos
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
Amplifying Signals via Enzymatic Cascade
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Mitogens and the Cell Cycle
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

